[EXEL] Exelixis, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Commercial Physical & Biological Resarch

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 15.41 Change: 0.47 (3.15%)
Ext. hours: 15.31 Change: -0.1 (-0.65%)

chart EXEL

Refresh chart

Strongest Trends Summary For EXEL

EXEL is in the medium-term down -26% below S&P in 1 year and down -37% below S&P in 2 years. In the long-term up 373% in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Phar

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 43.07% Sales Growth - Q/Q27.68% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-80.97% ROE156.1% ROI-102.16%
Current Ratio2.13 Quick Ratio2.09 Long Term Debt/Equity5.49 Debt Ratio-0.4
Gross Margin91.55% Operating Margin-615.77% Net Profit Margin-774.12% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-220 K Cash From Investing Activities49.9 M Cash From Operating Activities-45.09 M Gross Profit8.62 M
Net Profit-35.17 M Operating Profit-22.76 M Total Assets282.93 M Total Current Assets125.04 M
Total Current Liabilities58.68 M Total Debt368.43 M Total Liabilities429.69 M Total Revenue9.39 M
Technical Data
High 52 week24.76 Low 52 week13.65 Last close16.79 Last change2.5%
RSI23.17 Average true range0.64 Beta1.52 Volume4.05 M
Simple moving average 20 days-5.57% Simple moving average 50 days-12.22% Simple moving average 200 days-20.29%
Performance Data
Performance Week1.63% Performance Month-13.01% Performance Quart-22.66% Performance Half-26.52%
Performance Year3.39% Performance Year-to-date-14.64% Volatility daily1.91% Volatility weekly4.26%
Volatility monthly8.74% Volatility yearly30.26% Relative Volume263.48% Average Volume2.6 M
New High New Low

News

2020-05-28 06:58:47 | Is There An Opportunity With Exelixis, Inc.'s NASDAQ:EXEL 49% Undervaluation?

2020-05-20 13:30:14 | 3 Charts That Suggest Biotech Stocks Are Headed Higher

2020-05-13 17:00:00 | Exelixis Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types

2020-05-13 09:54:00 | Better Buy: bluebird bio vs. Exelixis

2020-05-06 16:05:00 | Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May

2020-05-06 11:40:03 | Exelixis EXEL Q1 Earnings and Revenues Surpass Estimates

2020-05-06 05:23:49 | Edited Transcript of EXEL earnings conference call or presentation 5-May-20 9:00pm GMT

2020-05-06 01:01:17 | Exelixis Inc EXEL Q1 2020 Earnings Call Transcript

2020-05-05 18:25:10 | Exelixis EXEL Q1 Earnings and Revenues Beat Estimates

2020-05-05 16:05:00 | Exelixis Announces First Quarter 2020 Financial Results and Provides Corporate Update

2020-05-05 15:00:00 | Exelixis, Inc. to Host Earnings Call

2020-05-01 13:14:00 | Exelixis Charts Are Pointed Higher, Look to Buy a Dip

2020-04-28 12:33:04 | Earnings Preview: Exelixis EXEL Q1 Earnings Expected to Decline

2020-04-22 10:30:02 | Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More

2020-04-22 09:00:55 | How Does Exelixis's NASDAQ:EXEL P/E Compare To Its Industry, After Its Big Share Price Gain?

2020-04-21 16:05:00 | Exelixis to Release First Quarter 2020 Financial Results on Tuesday, May 5, 2020

2020-04-21 12:59:04 | Company News for Apr 21, 2020

2020-04-21 12:43:00 | Exelixis Stock Strength Jumps On Positive Cancer Treatment Results

2020-04-20 18:01:59 | How this East Bay biotech pushed past the 'negativity' with a big boost to its kidney cancer drug

2020-04-20 16:19:23 | This Biotech Stock Just Blew Into A Profit-Taking Zone — Here's Why

2020-04-20 11:03:00 | Kidney Cancer Drug From Bristol-Myers and Exelixis Meets Key Phase III Endpoint

2020-04-20 07:12:00 | Exelixis, Bristol-Myers stocks get a boost from upbeat trial results of a Kidney cancer treatment

2020-04-20 06:59:00 | CORRECTED-Bristol Myers says Opdivo performs well in kidney, lung cancer trials

2020-04-20 06:59:00 | Bristol Myers Squibb and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo® nivolumab in Combination with CABOMETYX® cabozantinib in Previously Untreated Advanced Renal Cell Carcinoma

2020-04-09 11:40:03 | EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?

2020-04-08 16:05:00 | Exelixis to Webcast Virtual Fireside Chat as Part of the Needham Healthcare Conference on April 15, 2020

2020-03-26 15:41:53 | Were These Hedge Funds Right About Selling Exelixis, Inc. EXEL?

2020-03-26 11:30:03 | Why Is Exelixis EXEL Down 15.6% Since Last Earnings Report?

2020-03-25 03:01:00 | Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® cabozantinib Tablets for the Treatment of Curatively Unresectable or Metastatic Renal Cell Carcinoma

2020-03-24 11:40:03 | EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?

2020-03-17 07:02:25 | A Sliding Share Price Has Us Looking At Exelixis, Inc.'s NASDAQ:EXEL P/E Ratio

2020-03-02 16:05:00 | Exelixis Announces George A. Scangos, Ph.D. to Retire From Its Board of Directors

2020-02-27 06:19:43 | Exelixis, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

2020-02-27 00:31:17 | Edited Transcript of EXEL earnings conference call or presentation 25-Feb-20 10:00pm GMT

2020-02-26 16:05:00 | Exelixis Announces Webcasts of Investor Conference Presentations in March

2020-02-26 10:03:03 | Exelixis EXEL Beats on Earnings, Misses on Sales in Q4

2020-02-25 18:35:11 | Exelixis EXEL Tops Q4 Earnings Estimates

2020-02-25 16:06:00 | Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Relapsed Radioiodine-Refractory Differentiated Thyroid Cancer

2020-02-25 16:05:00 | Exelixis Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

2020-02-21 11:30:04 | Exelixis EXEL to Report Q4 Earnings: What's in the Cards?

2020-02-19 07:28:50 | The Exelixis NASDAQ:EXEL Share Price Has Soared 689%, Delighting Many Shareholders

2020-02-12 16:05:00 | Exelixis to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 25, 2020

2020-02-12 14:10:26 | 3 Mid-Cap Growth Stocks to Buy

2020-02-11 17:50:10 | Exelixis EXEL Outpaces Stock Market Gains: What You Should Know

2020-02-11 07:23:06 | The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

2020-02-10 17:00:00 | Exelixis Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

2020-02-04 17:50:10 | Exelixis EXEL Gains But Lags Market: What You Should Know

2020-01-29 08:30:46 | The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut

2020-01-29 02:01:00 | Exelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX® cabozantinib for Advanced Hepatocellular Carcinoma

2020-01-28 09:52:32 | How Alameda — again — became a biotech hotspot